Dipeptidyl Peptidase-4 Inhibitors in the Elderly: More Benefits or Risks?

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Advances in Therapy

• Publication date

  2012-03-08

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s12325-012-0008-xPMID 22411425
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial

  2011cited by this paper
• Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International working group on sarcopenia.

  2011cited by this paper
• Long‐term treatment with the dipeptidyl peptidase‐4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52‐week efficacy and safety study

  2011cited by this paper
• Efficacy and safety of saxagliptin in older patients with type 2 diabetes mellitus

  2011cited by this paper
• Predictors of response to dipeptidyl peptidase‐4 inhibitors: evidence from randomized clinical trials

  2011influential reference
• Dipeptidyl Peptidase-4 Inhibitors and Bone Fractures

  2011cited by this paper
• Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24‐week randomized placebo‐controlled trial

  2011cited by this paper
• International working group on Sarcopenia

  2011cited by this paper
• Comparative Effectiveness and Safety of Medications for Type 2 Diabetes: An Update Including New Drugs and 2-Drug Combinations

  2011cited by this paper
• Antidiabetic treatments and risk of hospitalisation with myocardial infarction: a nationwide case–control study

  2011cited by this paper
• Incretin Therapies in the Management of Elderly Patients with Type 2 Diabetes Mellitus

  2011cited by this paper
• Use of Dipeptidyl Peptidase-4 Inhibitors and the Reporting of Infections: A Disproportionality Analysis in the World Health Organization VigiBase

  2011cited by this paper
• Effect of Antihyperglycemic Agents Added to Metformin and a Sulfonylurea on Glycemic Control and Weight Gain in Type 2 Diabetes: A Network Meta-analysis

  2011cited by this paper
• Characterization of macro-and microvascular function and structure in patients with type 2 diabetes mellitus.

  2011cited by this paper
• Clinical experience with vildagliptin in the management of type 2 diabetes in a patient population ≥75 years: a pooled analysis from a database of clinical trials

  2011cited by this paper
• Comment on: American Diabetes Association. Standards of Medical Care in Diabetes—2011. Diabetes Care 2011;34(Suppl. 1):S11–S61

  2011cited by this paper
• Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials

  2011cited by this paper
• Dipeptydil peptidase-4 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials.

  2010cited by this paper
• Relationships Between Daily Acute Glucose Fluctuations and Cognitive Performance Among Aged Type 2 Diabetic Patients

  2010cited by this paper
• Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes

  2010cited by this paper
• Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis

  2010cited by this paper
• The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study

  2010cited by this paper
• Standards of Medical Care in Diabetes—2010

  2010cited by this paper
• Pharmacokinetics of dipeptidylpeptidase‐4 inhibitors

  2010cited by this paper
• The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study

  2010cited by this paper
• Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes

  2010cited by this paper
• Avoiding hypoglycaemia while achieving good glycaemic control in type 2 diabetes through optimal use of oral agent therapy

  2010influential reference
• Moving against frailty: does physical activity matter?

  2010cited by this paper
• Type 2 diabetes and risk for functional decline and disability in older persons.

  2010cited by this paper
• An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials

  2010cited by this paper
• Alogliptin

  2010cited by this paper
• Effects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations.

  2010cited by this paper
• Key priorities in managing glucose control in older people with diabetes

  2009cited by this paper
• Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus.

  2009cited by this paper
• Prevention of cardiovascular disease through glycemic control in type 2 diabetes: a meta-analysis of randomized clinical trials.

  2009cited by this paper
• Pharmacologic management of the older patient with type 2 diabetes mellitus.

  2009cited by this paper
• Neurocognitive impairment and comorbid depression in patients of diabetes mellitus

  2009cited by this paper
• Intensive glycemic control and the prevention of cardiovascular events:implications of the ACCORD,ADVANCE,and VA Diabetes Trials

  2009cited by this paper
• Comparison of vildagliptin and thiazolidinedione as add‐on therapy in patients inadequately controlled with metformin: results of the GALIANT trial – a primary care, type 2 diabetes study

  2009cited by this paper
• Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials

  2009cited by this paper
• Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24‐week, double‐blind, randomized trial

  2009cited by this paper
• Alogliptin Use in Elderly People: A Pooled Analysis from Phase 2 and 3 Studies

  2009cited by this paper
• Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials.

  2009cited by this paper
• New Approaches to Treating Type 2 Diabetes Mellitus in the Elderly

  2008cited by this paper
• Hypoglycaemia in Type 2 diabetes

  2008cited by this paper
• A Meta-analysis of Randomized Clinical Trials

  2008cited by this paper
• Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency

  2008cited by this paper
• The growing burden of diabetes mellitus in the US elderly population.

  2008cited by this paper
• Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes

  2007cited by this paper
• Management of Type 2 Diabetes in Treatment-Naive Elderly Patients

  2007cited by this paper
• Comparison of Vildagliptin and Rosiglitazone Monotherapy in Patients With Type 2 Diabetes

  2007cited by this paper
• Bone Fractures and Hypoglycemic Treatment in Type 2 Diabetic Patients

  2007cited by this paper
• Body mass index history and risk of type 2 diabetes: results from the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study.

  2006cited by this paper
• Psychiatric Disorders and Psychotropic Medication Use in Elderly Persons with Diabetes

  2006cited by this paper
• Standards of medical care in diabetes.

  2006cited by this paper
• The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.

  2006cited by this paper
• Body mass index history and risk of type 2 diabetes: results from the European Prospective Investigation into Cancer and Nutrition

  2006cited by this paper
• Use of antidiabetic drugs in elderly patients.

  2005cited by this paper
• Burden of diabetes in an aging population: prevalence, incidence, mortality, characteristics and quality of care.

  2005cited by this paper
• Caring the elderly diabetic patient with respect to concepts of successful aging and frailty.

  2005cited by this paper
• Hypoglycaemia in elderly patients with diabetes mellitus: causes and strategies for prevention.

  2004cited by this paper
• Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes.

  2004cited by this paper
• The prevalence of diabetic retinopathy among adults in the United States.

  2004cited by this paper
• Hypoglycaemia in Elderly Patients with Diabetes Mellitus

  2004cited by this paper
• Oxford textbook of geriatric medicine, 2nd Edition. Edited by J. Grimley Evans, T. Franklin Williams, B. Lynn Beattie, J.-P. Michel and G. K. Wilcock. Oxford University Press, Oxford, 2000. Pages: 1264. £175.00

  2003cited by this paper
• Older women with diabetes have a higher risk of falls: a prospective study.

  2002influential reference
• Effects of treatment with sulfonylurea drugs or insulin on ischemia-induced myocardial dysfunction in type 2 diabetes.

  2002cited by this paper
• Initial Management of Glycemia in Type 2 Diabetes Mellitus

  2002influential reference
• Clinical practice. Initial management of glycemia in type 2 diabetes mellitus.

  2002cited by this paper
• Diabetes in elderly adults.

  2001cited by this paper
• Changes in cognitive abilities over a 4-year period are unfavorably affected in elderly diabetic subjects: results of the Epidemiology of Vascular Aging Study.

  2001cited by this paper
• Mortality in older people with diabetes mellitus

  1997cited by this paper
• Oxford Textbook of Geriatric Medicine

  1993cited by this paper

• Empagliflozin Improves Learning and Memory Deficits in Streptozotocin-Induced Hyperglycemic Male Wistar Rats.

  2026cites this paper
• [Evolution of the non-insulin therapeutic strategy in type 2 diabetes].

  2023cites this paper
• Dose decision of HSK7653 oral immediate release tablets in specific populations clinical trials based on mechanistic physiologically-based pharmacokinetic model

  2023cites this paper
• Choix entre une gliptine et une gliflozine chez le patient âgé avec un diabète de type 2

  2022cites this paper
• Cognitive impairment and Type 2 Diabetes Mellitus: Focus of SGLT2 Inhibitors Treatment.

  2022cites this paper
• DPP4 inhibitors as a potential therapeutic option for sarcopenia: A 6-month follow-up study in diabetic older patients.

  2022cites this paper
• Treatment Patterns of Type 2 Diabetes Assessed Using a Common Data Model Based on Electronic Health Records of 2000–2019

  2021cites this paper
• Which antidiabetic drug indications are recommended for geriatric DM patients?

  2021cites this paper
• Comparison of Adverse Kidney Outcomes With Empagliflozin and Linagliptin Use in Patients With Type 2 Diabetic Patients in a Real-World Setting

  2021cites this paper
• Careful use to minimize adverse events of oral antidiabetic medications in the elderly

  2021cites this paper
• Efficacy / safety balance of DPP-4 inhibitors versus SGLT2 inhibitors in elderly patients with type 2 diabetes.

  2021cites this paper
• Efficacy and safety of metformin and sitagliptin‐based dual and triple therapy in elderly Chinese patients with type 2 diabetes: Subgroup analysis of STRATEGY study

  2020cites this paper
• Hospital Admissions Associated With Medication-Related Problems in Thai Older Patients: A Multicenter Prospective Observational Study

  2019cites this paper
• The Role of DPP-4 Inhibitors in the Treatment Algorithm of Type 2 Diabetes Mellitus: When to Select, What to Expect

  2019cites this paper
• Diabetes and Aging: From Treatment Goals to Pharmacologic Therapy

  2019cites this paper
• Effects of vildagliptin, a DPP-4 inhibitor, in elderly diabetic patients with mild cognitive impairment.

  2019cites this paper
• The safety of gliptins : updated data in 2018

  2018cites this paper
• When metformin is not enough: Pros and cons of SGLT2 and DPP‐4 inhibitors as a second line therapy

  2018cites this paper
• Effects of saxagliptin on glucose homeostasis and body composition of obese patients with newly diagnosed pre-diabetes.

  2017cites this paper
• Dapagliflozin and saxagliptin tablets for adults with type 2 diabetes

  2017cites this paper
• Pharmacokinetic drug evaluation of saxagliptin plus dapagliflozin for the treatment of type 2 diabetes

  2017cites this paper
• Efficacy and safety of saxagliptin and metformin as initial combination therapy in patients with type 2 diabetes : a meta-analysis

  2016cites this paper
• Efficacy, safety and impact on β-cell function of dipeptidyl peptidase-4 inhibitors plus metformin combination therapy in patients with type 2 diabetes and the difference between Asians and Caucasians: a meta-analysis

  2016cites this paper
• Sarcopenia in Elderly Diabetic Patients: Role of Dipeptidyl Peptidase 4 Inhibitors.

  2016cites this paper
• Type 2 Diabetes Mellitus and the Elderly: An Update on Drugs Used to Treat Glycaemia.

  2016cites this paper
• Hoofdstuk 9 (Farmaco)therapie van diabetes mellitus type 2 bij de oudere patiënt

  2015cites this paper
• Hoofdstuk 13 De obese diabetespatiënt op oudere leeftijd

  2015cites this paper
• Insulin therapy in the elderly with type 2 diabetes.

  2015cites this paper
• Response: Predictive Factors for Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2015;39:342-7)

  2015cites this paper
• Dipeptidyl peptidase‐4 inhibitors can minimize the hypoglycaemic burden and enhance safety in elderly people with diabetes

  2015cites this paper
• The older patient with diabetes: a practical approach

  2014cites this paper
• Efficacy and safety of dipeptidyl peptidase‐4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta‐analysis

  2014cites this paper
• Incretin-based therapies, glucometabolic health and endovascular inflammation.

  2014influential citation
• Dipeptidyl peptidase-4 inhibitors have protective effect on cognitive impairment in aged diabetic patients with mild cognitive impairment.

  2014cites this paper
• Optimal therapy of type 2 diabetes: a controversial challenge

  2014cites this paper
• DPP-4 Inhibitors as a New Option for the Management of Type 2 Diabetes

  2013cites this paper
• Risk Factors for Adverse Symptoms During Dipeptidyl Peptidase-IV Inhibitor Therapy: A Questionnaire-Based Study Carried Out by the Japan Pharmaceutical Association Drug Event Monitoring Project in Kumamoto Prefecture

  2013cites this paper
• GLP-1 receptor agonists or DPP-4 inhibitors: how to guide the clinician?

  2013cites this paper
• Metformin revisited: a critical review of the benefit-risk balance in at-risk patients with type 2 diabetes.

  2013cites this paper
• Efficacy and safety of Jentadueto® (linagliptin plus metformin)

  2013cites this paper
• Incretin therapy for type 2 diabetes: GLP-1 receptor agonists and DPP-4 inhibitors

  2013cites this paper
• Agonistes des récepteurs du GLP-1 ou inhibiteurs de la DPP-4 : comment orienter le choix du clinicien ?

  2012cites this paper
• Adverse Drug Events as a Cause of Hospitalization in Older Adults

  2012cites this paper
• Vascular Health and Risk Management Dovepress Linagliptin as Add-on Therapy to Insulin for Patients with Type 2 Diabetes

  year unknowncites this paper